Mike Nally, Generate:Biomedicines CEO

Flag­ship’s AI uni­corn Gen­er­ate rais­es $273M Se­ries C, as first drug in 17-pro­gram pipeline en­ters the clin­ic

Flag­ship Pi­o­neer­ing’s AI-fo­cused start­up Gen­er­ate:Bio­med­i­cines has raised an­oth­er megaround that will push mul­ti­ple drug pro­grams in­to the clin­ic.

The Somerville, MA-based biotech said Thurs­day it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.